10.99
price down icon6.39%   -0.75
 
loading
Surrozen Inc stock is traded at $10.99, with a volume of 11,378. It is down -6.39% in the last 24 hours and up +0.27% over the past month.
See More
Previous Close:
$11.74
Open:
$11
24h Volume:
11,378
Relative Volume:
0.42
Market Cap:
$35.72M
Revenue:
-
Net Income/Loss:
$-53.45M
P/E Ratio:
-0.5062
EPS:
-21.71
Net Cash Flow:
$-31.81M
1W Performance:
-0.18%
1M Performance:
+0.27%
6M Performance:
-2.74%
1Y Performance:
-3.00%
1-Day Range:
Value
$10.74
$11.56
1-Week Range:
Value
$10.74
$12.93
52-Week Range:
Value
$5.9999
$18.17

Surrozen Inc Stock (SRZN) Company Profile

Name
Name
Surrozen Inc
Name
Phone
650-475-2820
Name
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-08-16
Name
Latest SEC Filings
Name
SRZN's Discussions on Twitter

Compare SRZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SRZN
Surrozen Inc
10.99 35.72M 0 -53.45M -31.81M -21.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Surrozen Inc Stock (SRZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-30-25 Initiated H.C. Wainwright Buy
Jan-03-25 Upgrade Guggenheim Neutral → Buy
Oct-11-21 Initiated BofA Securities Buy
Sep-15-21 Initiated Guggenheim Buy
Sep-07-21 Initiated Stifel Buy

Surrozen Inc Stock (SRZN) Latest News

pulisher
Apr 04, 2025

When (SRZN) Moves Investors should Listen - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 03, 2025

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com

Apr 03, 2025
pulisher
Apr 02, 2025

Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Surrozen (SRZN) to Release Earnings on Wednesday - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Surrozen Focuses on Ophthalmology Amid Financial Challenges - TipRanks

Apr 02, 2025
pulisher
Mar 31, 2025

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Surrozen Lands Massive $175M Deal: What This Means for Its Eye Disease Pipeline - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Surrozen sees $11.9 million in stock purchases by Column Group - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Surrozen Secures $76.4M in Private Placement Deal - TipRanks

Mar 28, 2025
pulisher
Mar 25, 2025

Surrozen drops hepatitis drug after Phase I flop - Yahoo

Mar 25, 2025
pulisher
Mar 24, 2025

Surrozen shifts focus to eye disease treatments, secures $175M funding - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen to Raise Up to $175 Million in Private Placement; Fine-Tunes Ophthalmology Clinical Programs - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen shifts focus to eye disease treatments, secures $175M funding By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Major Pivot: Surrozen Lands $175M to Develop Breakthrough Eye Disease Treatments - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

(SRZN) Trading Advice - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 10, 2025

Reviewing Surrozen (NASDAQ:SRZN) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld MedTech

Mar 07, 2025
pulisher
Mar 03, 2025

(SRZN) On The My Stocks Page - Stock Traders Daily

Mar 03, 2025
pulisher
Mar 03, 2025

Week Ahead (Sep.13- 17): FDA Decision, Data Readouts (CALT, ASLN, LIFE…) - RTTNews

Mar 03, 2025
pulisher
Feb 26, 2025

Better Warren Buffett Stock: Nu Holdings vs. Bank of America - The Globe and Mail

Feb 26, 2025
pulisher
Feb 21, 2025

(SRZN) Trading Signals - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 12, 2025

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating - MSN

Feb 12, 2025
pulisher
Feb 10, 2025

How To Trade (SRZN) - Stock Traders Daily

Feb 10, 2025
pulisher
Feb 07, 2025

Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com

Feb 07, 2025
pulisher
Feb 03, 2025

HC Wainwright Predicts Surrozen FY2024 Earnings - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Surrozen (NASDAQ:SRZN) Research Coverage Started at HC Wainwright - Defense World

Feb 02, 2025
pulisher
Jan 30, 2025

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jan 30, 2025
pulisher
Jan 30, 2025

HC Wainwright Initiates Coverage on Surrozen With Buy Rating, $32 Price Target -January 30, 2025 at 08:15 am EST - Marketscreener.com

Jan 30, 2025
pulisher
Jan 29, 2025

REGENTS OF THE UNIVERSITY OF CALIFORNIA Acquires Significant Sta - GuruFocus.com

Jan 29, 2025
pulisher
Jan 28, 2025

REGENTS OF THE UNIVERSITY OF CALIFORNIA Acquires Shares in Surro - GuruFocus.com

Jan 28, 2025
pulisher
Jan 22, 2025

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation - Yahoo Finance

Jan 22, 2025
pulisher
Jan 19, 2025

(SRZN) Trading Report - Stock Traders Daily

Jan 19, 2025
pulisher
Jan 16, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market SessionAditxt (NASDAQ:ADTX), Aclarion (NASDAQ:ACON) - Benzinga

Jan 16, 2025
pulisher
Jan 16, 2025

Financial Analysis: Recursion Pharmaceuticals (NASDAQ:RXRX) versus Surrozen (NASDAQ:SRZN) - Defense World

Jan 16, 2025
pulisher
Jan 06, 2025

Surrozen exec vice president sells $14,642 in stock - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Surrozen exec vice president sells $14,642 in stock By Investing.com - Investing.com UK

Jan 06, 2025
pulisher
Jan 06, 2025

Surrozen's CFO and COO sells $20,513 in stock - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Surrozen's CFO and COO sells $20,513 in stock By Investing.com - Investing.com UK

Jan 06, 2025
pulisher
Jan 04, 2025

Surrozen (NASDAQ:SRZN) Upgraded by Guggenheim to “Buy” Rating - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

Surrozen stock soars to 52-week high, hits $16.35 - Investing.com

Jan 03, 2025
pulisher
Jan 03, 2025

Block upgraded, Bumble downgraded: Wall Street's top analyst calls - Yahoo Finance

Jan 03, 2025
pulisher
Dec 29, 2024

(SRZN) Investment Analysis and Advice - Stock Traders Daily

Dec 29, 2024
pulisher
Dec 24, 2024

Financial Review: Surrozen (NASDAQ:SRZN) & Vericel (NASDAQ:VCEL) - Defense World

Dec 24, 2024
pulisher
Dec 18, 2024

Learn to Evaluate (SRZN) using the Charts - Stock Traders Daily

Dec 18, 2024
pulisher
Dec 08, 2024

When the Price of (SRZN) Talks, People Listen - Stock Traders Daily

Dec 08, 2024
pulisher
Dec 04, 2024

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky - Simply Wall St

Dec 04, 2024

Surrozen Inc Stock (SRZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):